PLX8394

PLX8394 is a next-generation, orally available, small-molecule BRAF inhibitor with IC50 values of 3.8 nM, 14 nM and 23 nM for BRAF(V600E), WT BRAF and CRAF respectively. It has potential antineoplastic activity.


Cat. No.: EX-A1461	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	450	In-stock
250mg	850	In-stock
500mg	1450	In-stock
1g	2350	In-stock
5g	5850	In-stock
10g	8775	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	1393466-87-9
Purity	>98%
Formula	C25H21F3N6O3S
Mol Weight	542.533
Appearance	Solid powder
Solubility	soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Tutuka CSA, Andrews MC, Mariadason JM, et al. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. Mol Cancer. 2017;16(1):112. Published 2017 Jun 28. doi:10.1186/s12943-017-0684-x [2]. Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(3):479-484. doi:10.1111/pcmr.12218 [3]. Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016;113(47):13456-13461. doi:10.1073/pnas.1610456113 [4]. Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526(7574):583-586. doi:10.1038/nature14982
CoA	CoA of PLX8394

Smiles:	F[C@@H]1CCN(C1)S(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CN=C(N=C2)C2CC2)=C(F)C=C1


		Search